RxDoctor Payments Data

Khalid Butt, MD

Family Medicine · Bainbridge, NYNPI 1982676060

Payments from drug & device makers

$2,841in general payments, 2019–2025

Across 165 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$580
  • GSK$342
  • Pfizer$291
  • Novo Nordisk$268
  • Merck$215
  • Boehringer Ingelheim$191
  • plus $953 from 16 others

What the payments were for

  • Food & beverage$2,841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,841 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$60,548
Medicare patients
186
Services billed
917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$84,511
JanumetSitagliptin Phos/Metformin Hcl57$59,960
JardianceEmpagliflozin20$32,957
OzempicSemaglutide23$28,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$28,314
JanuviaSitagliptin Phosphate20$27,143
Janumet XrSitagliptin Phos/Metformin Hcl20$25,191
TrulicityDulaglutide19$24,442
JentaduetoLinagliptin/Metformin Hcl14$17,045
VascepaIcosapent Ethyl14$14,398
Breo ElliptaFluticasone/Vilanterol19$13,504
XareltoRivaroxaban15$11,886
MyrbetriqMirabegron17$10,604
Pioglitazone-GlimepiridePioglitazone Hcl/Glimepiride12$7,575
Levemir FlexpenInsulin Detemir11$6,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr$215$112,29497 claims
PfizerEliquis$291$84,51170 claims
Boehringer IngelheimJardiance, Jentadueto$191$50,00234 claims
GSKTrelegy Ellipta, Breo Ellipta$342$41,81842 claims
Novo NordiskOzempic$268$28,40723 claims
Lilly USA, LLCTrulicity$49$24,44219 claims
Johnson & JohnsonXarelto$168$11,88615 claims
Astellas Pharma US IncMyrbetriq$33$10,60417 claims
AstraZenecaSymbicort$580$5,55517 claims
AbbVieSynthroid$122$2,11924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bainbridge

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →